# Incyte

Source: https://onco.cc/companies/incyte/  
OnCo record `incyte` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Incyte makes pemigatinib, the first targeted drug approved for bile duct cancer (2020), and the JAK inhibitor ruxolitinib.

## Summary

Incyte, based in Wilmington, Delaware, and listed as INCY, makes pemigatinib, sold as Pemazyre, the first targeted drug approved for bile duct cancer in 2020, and the JAK inhibitor ruxolitinib, proved in COMFORT-I for myelofibrosis. Pemigatinib was approved for FGFR2-fusion cholangiocarcinoma on the FIGHT-202 trial, but the first-line FIGHT-302 trial against gemcitabine and cisplatin was discontinued; the company also markets tafasitamab with MorphoSys for diffuse large B-cell lymphoma and retifanlimab, and it developed the failed IDO1 inhibitor epacadostat. OnCo links it to biliary tract cancer, lymphoma, anal cancer, Merkel cell carcinoma and myeloproliferative neoplasms. Whether FGFR inhibition can move earlier in bile duct cancer after FIGHT-302 stopped is the open question. Each product has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- Also known as: Incyte (incl. MorphoSys US rights)
- HQ: Wilmington, DE
- Type: biotech
- Website: https://www.incyte.com
- Ticker: INCY

## Notes

- Incyte holds worldwide rights to tafasitamab (Monjuvi) after the MorphoSys deal. frontMIND (Lancet 2026) showed tafasitamab plus lenalidomide and R-CHOP improved progression-free survival against R-CHOP in high-risk newly diagnosed DLBCL (HR 0.75), the first frontline win over R-CHOP in decades, with a supplemental BLA planned for the first half of 2026.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Incyte
- Official website: https://www.incyte.com

## Connected records

- cancers: [Anal cancer (squamous cell carcinoma)](https://onco.cc/cancers/anal/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Epacadostat](https://onco.cc/drugs/epacadostat/), [INCA033989](https://onco.cc/drugs/inca033989/), [INCA33890](https://onco.cc/drugs/inca33890/), [INCB123667](https://onco.cc/drugs/incb123667/), [INCB161734](https://onco.cc/drugs/incb161734/), [Parsaclisib](https://onco.cc/drugs/parsaclisib/), [Pemigatinib](https://onco.cc/drugs/pemigatinib/), [Retifanlimab](https://onco.cc/drugs/retifanlimab/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/)
- trials: [A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa](https://onco.cc/trials/nct04680052/), [A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression](https://onco.cc/trials/nct07023627/), [A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma](https://onco.cc/trials/nct07522073/), [A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection a](https://onco.cc/trials/nct07823322/), [A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive](https://onco.cc/trials/nct05879822/), [A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer](https://onco.cc/trials/nct07284849/), [AALL1521](https://onco.cc/trials/aall1521/), [An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib](https://onco.cc/trials/nct02955940/), [COMFORT-I](https://onco.cc/trials/comfort-i/), [Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct03516708/), [Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab](https://onco.cc/trials/nct06465433/), [FIGHT-202](https://onco.cc/trials/fight-202/), [FIGHT-302](https://onco.cc/trials/fight-302/), [frontMIND](https://onco.cc/trials/frontmind/), [INTUITT-NF2](https://onco.cc/trials/intuitt-nf2/), [Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct03348904/), [Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)](https://onco.cc/trials/nct03260894/), [Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)](https://onco.cc/trials/nct03358472/), [POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)](https://onco.cc/trials/pod1um-201/), [POD1UM-303/InterAACT-2](https://onco.cc/trials/pod1um-303/), [RESPONSE](https://onco.cc/trials/response/), [Retifanlimab and Ruxolitinib In Solid Malignancies](https://onco.cc/trials/nct07219576/), [Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)](https://onco.cc/trials/nct04509700/), [Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors](https://onco.cc/trials/nct03934372/), [Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients](https://onco.cc/trials/nct05222555/), [Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck](https://onco.cc/trials/nct05287113/), [Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression](https://onco.cc/trials/nct07214779/), [Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (](https://onco.cc/trials/nct05429268/), [To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL](https://onco.cc/trials/nct04661007/)
- ideas: [RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression](https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/)
- key papers: [COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis](https://onco.cc/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/), [Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial](https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- companies: [Genesis Molecular AI (formerly Genesis Therapeutics)](https://onco.cc/companies/genesis-molecular-ai/)

---
JSON: https://onco.cc/api/v1/entities/incyte.json